|
 |
RenagelThis page contains recent news articles, when available, and an overview of Renagel but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The increase was primarily due to higher sales of Cerezyme ((imiglucerase for injection), Fabrazyme (agalsidase beta), Renagel (sevelamer hydrochloride), ... OfficialWire (press release) Genzyme Launches Renvela Powder in US - Nov 10, 2009 Renvela was launched in March 2008 and is a next-generation version of Renagel, which Genzyme said is the most-prescribed phosphate binder in the United ... Renal Business Today Genzyme Corporation Q3 2009 Earnings Call Transcript - Oct 21, 2009 In the cardio metabolic and renal area, we increased by about 7% to $261 million, both Renagel and Renvella increased with greater unit volume as well as ... Seeking Alpha (blog) Genzyme Reports Third-Quarter Financial Results - Oct 22, 2009 Within this segment, sales of Genzyme's sevelamer therapies, Renvela ® (sevelamer carbonate) and Renagel ® (sevelamer hydrochloride), were $181.7 million in ... Business Wire (press release) Genzyme 盈馀低於预期，股价下跌4% - Oct 21, 2009 ...第三å£Cerezymeè?¯å“?销售é¢?为9360万美元，市场预期1.01忆美元；Renagel销售é¢?1.817忆美元，市场预期1.8忆美元；Fabrazyme销售é¢?1.152忆美元，市场预期1.14亿 ... 凤凰网 Genzyme 盈餘低於é ?期，股價下跌4% - Oct 21, 2009 ...第三å£Cerezymeè—¥å“?銷售é¡?為9360è?¬ç¾Žå…ƒï¼Œå¸‚å ´é ?期1.01憶美元；Renagel銷售é¡?1.817æ†¶ç¾Žå…ƒï¼Œå¸‚å ´é ?期1.8憶美元；Fabrazyme銷售é¡?1.152æ†¶ç¾Žå…ƒï¼Œå¸‚å ´é ?期1.14å„„ ... 環球財經 Genzyme's Near-Term Growth Seen Driven By Renagel - Apr 20, 2006 Piper Jaffray lowered the price target on Genzyme to $83 from $91 following the biotech company's first-quarter earnings report. ... Forbes Genzyme drug gets a boost. - Jul 29, 2005 29--Genzyme Corp. said yesterday its kidney dialysis drug Renagel cut the death ... Renagel, a pill for which the Cambridge biotech company charges $1500 to ... Free with registration - Boston Globe - AccessMyLibrary.com Genzyme's Renagel Seen With Long-Term Effectiveness - Nov 11, 2005 Credit Suisse First Boston maintained an "outperform" rating on Genzyme (nasdaq: GENZ - news - people ) after the biotech firm released trial data for ... Forbes Genzyme kidney drug lowers death rate in trial - Jan 8, 2007 O) said on Monday that patients taking its kidney disease drug Renagel had a ... Patients either received Renagel or a calcium-based phosphate binder and ... Reuters Genzyme reports lower profit on Isis deal charges - Apr 23, 2008 Its second best-selling therapy, Renagel, had sales of $168.7 million, up 23%. The drug is used in conjunction with kidney dialysis. ... MarketWatch Genzyme cites mixed results for Renvela powder - Jun 18, 2007 Renagel is used to control excessive levels of phosphate in the blood of patients with kidney disease who are undergoing dialysis. Elevated blood levels of ... Reuters … Complementary Therapy to Renagel; Accelerates Commercial Entry... - May 4, 2005 The use of Renagel and Hectorol are each supported by a large and growing ... Renagel has an established safety profile, is not systemically absorbed and ... Wisbusiness.com Analysts React To Genzyme Earnings - Jul 12, 2006 ..."We expect sales of [Renagel, Cerezyme, Fabrazyme] to remain strong, and we are positive on the potential for Myozyme, as well as several other late-stage ... Forbes FDA OKs Genzyme's Renvela - Oct 22, 2007 Renagel will still be available, though Genzyme's long-term goal is to transition patients to Renvela. In clinical trials, patients on Renvela had a lower ... TheStreet.com - TheStreet.com (subscription) Genzyme launches kidney disease drug - Mar 6, 2008 It is a new version of the kidney disease drug Renagel, which was approved in 1998. Renvela is approved to control serum phosphorus in patients with chronic ... Forbes Genzyme says petition against Renagel 'inaccurate' - May 12, 2006 CAMBRIDGE, Mass. —A recent petition to the US Food and Drug Administration calling for the withdrawal of Genzyme Corp.'s phosphorus drug Renagel was ... Renal Business Today Genzyme May Benefit From Larger Renal Disease Market - Sep 27, 2005 The research firm said the question remains whether Renagel, ... "We expect Renagel to reaccelerate its growth in 2006 and 2007 as a result of more ... Forbes Genzyme 3rd-Quarter Profit Drops 86% on Acquisitions - Oct 12, 2006 The stock decline may also reflect investor concern that Renagel will face ... Sales of Renagel, used for controlling phosphorus in patients on kidney ... Bloomberg Renagel in New Dialysis Study Published in Kidney International - Jan 15, 2007 MISSAUGA, ON, CANADA -- January 15, 2007 -- Genzyme Canada announced today that findings published in the online version of Kidney International demonstrate ... DG News Nabi Biopharmaceuticals Announces Receipt of $2.5 Million Milest - Jun 3, 2008 This milestone payment was contingent on publication of information related to the CARE-2 (Calcium Acetate Renagel Evaluation-2) Study. ... Bloomberg Genzyme profits leap 58 percent in second quarter. - Jul 15, 2005 Renagel, which helps reduce phosphate buildup in kidney-dialysis patients, was developed by GelTex, a Waltham company later auired by Genzyme. ... Free with registration - Boston Globe - AccessMyLibrary.com Genzyme Sticks With Forecast - Feb 15, 2006 Revenue for Renagel, for patients with end-stage renal disease, is expected to reach $495 million to $505 million this year, compared with $417 million last ... TheStreet.com - TheStreet.com (subscription) Genzyme successfully tests kidney drug - Apr 16, 2007 Genzyme, a Cambridge biopharmaceutical company, has had success with Renagel, an existing treatment for patients with failed kidneys. ... Boston Globe Genzyme Blows Past Forecasts - Oct 18, 2005 Sales of Genzyme's biggest drug, Cerezyme for Gaucher disease, rose 14% from a year ago to $238.3 million, while sales of Renagel, a drug for kidney disease ... TheStreet.com - TheStreet.com (subscription) Genzyme Files for Approval of Sevelamer Carbonate for Patients on … - Dec 21, 2006 Renagel controls serum phosphorus in patients with CKD on hemodialysis. ... Renagel provides the added benefit of significant LDL cholesterol reduction (32 ... Free with registration - PR Newswire - AccessMyLibrary.com Genzyme Announces Publication of DCOR Study in Kidney International - Aug 30, 2007 However, a clinically meaningful benefit was associated with Renagel use for older ... In the Renagel group there were three events reported involving three ... allamericanpatriots.com … Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part... - Jan 17, 2008 Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Renagel Study in New Dialysis Patients Published in Kidney Internation... - Sep 29, 2005 CAMBRIDGE, Mass., Sept. 29 /PRNewswire-FirstCall/ -- Genzyme Corporation announced today that results from the Renagel in New Dialysis (RIND) study have ... $4.95 - PR Newswire - ECNext … Hospitalizations and Health Care Costs Associated with Renagel Use. - Nov 16, 2006 According to the study investigators, patients treated with Renagel achieved an 11.0 ... Patients treated with Renagel had costs that were, on average, ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Renagel in New Dialysis Study Published in Kidney … - Jan 8, 2007 Renagel in New Dialysis Study Published in Kidney International. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Renagel Study in New Dialysis Patients Published in … - Sep 29, 2005 Renagel Study in New Dialysis Patients Published in Kidney International. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … and Health Care Costs Associated with Renagel Use. - PR Newswire |... - Nov 16, 2006 Decreased Hospitalizations and Health Care Costs Associated with Renagel Use. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Fosrenol's Threat To Renagel May Be Leveling Off: Report - Apr 18, 2005 By Randall Osborne. Earlier this month, powerhouse Genzyme Corp. disclosed its launch of Phase III trials with the toxin binder tolevamer for patients with ... BioWorld Online - BioWorld Online Event Brief of Q4 2006 Genzyme Corporation Earnings Conference Call -... - Feb 14, 2007 I wanted to get the international and US, breakout of Renagel and also what your estimate of current share is with Renagel in the US Thanks. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com AKF, Genzyme launch Renagel assistance program - Jul 31, 2006 CAMBRIDGE--The American Kidney Fund and Genzyme Corp. have teamed up to launch a program that will provide Renagel to Medicare patients who can't afford ... Renal Business Today … Costs; American Kidney Fund teams with biotech firm for Renagel … - Mar 28, 2005 The Renagel Patient Assistance Program is intended for patients who have no ... In addition to RPAP, Genzyme's Renagel REACH Program was launched last year ... Pay-Per-View - Managed Care Weekly Digest - Factiva, from Dow Jones … Costs; American Kidney Fund teams with biotech firm for Renagel … - Mar 29, 2005 The Renagel Patient Assistance Program is intended for patients who have no ... In addition to RPAP, Genzyme's Renagel REACH Program was launched last year ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Genzyme submits NDA for Renagel's replacement - Dec 29, 2006 Executives say Renvela is under development to replace Renagel, ... Renvela comes in powder-based tablets taken once per day, while Renagel tablets are ... Mass High Tech Fresenius Medical Care Announces Positive Results From PhosLo CARE … - Nov 21, 2006 Patients treated with PhosLo and Renagel achieved comparable reductions in Serum-Phosphorus and Calcium-Phosphorus product and even more importantly K/DOQI ... RedOrbit Genzyme Reports Growth in First Quarter. - Apr 25, 2007 Within the Renal business, sales of Renagel (sevelamer hydrochloride) grew 16 ... Renagel continues to gain market share based on its demonstrated clinical ... $4.95 - M2 Presswire - ECNext Genzyme Looks to Carve Out Market Share for Renvela - Jun 30, 2008 ...based Genzyme launched Renagel back in 1998, John Butler, president of ... Renagel is the market leader in phosphate binders, according to a report by the ... Renal Business Today Renal Failure; Renagel study in new dialysis patients shows positive ... - Oct 30, 2005 2005 OCT 30 - (NewsRx.com) -- Genzyme Corporation (GENZ) announced that results from the Renagel in New Dialysis (RIND) study were published in the October ... Pay-Per-View - Heart Disease Weekly - Factiva, from Dow Jones Renal Failure; Renagel study in new dialysis patients shows positive ... - Oct 24, 2005 2005 OCT 24 - (NewsRx.com) -- Genzyme Corporation (GENZ) announced that results from the Renagel in New Dialysis (RIND) study were published in the October ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Q3 2006 Genzyme Corporation Earnings Conference Call - Final. - Oct 12, 2006 The second thing that worked beautifully during this quarter, again, after the strong second quarter, was Renagel. In fact, Renagel has grown more ever ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genzyme Corporation; Renagel study in new dialysis patients shows … - Oct 26, 2005 2005 OCT 26 - (NewsRx.com) -- Genzyme Corporation (GENZ) announced that results from the Renagel in New Dialysis (RIND) study were published in the October ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Large Proportion of Patients on Renagel(R) Receive Calcium … - Nov 21, 2005 ROCKVILLE, Md., Nov. 21 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals announced the results of a study conducted by Charles Nolan, MD, professor, ... $4.95 - PR Newswire - ECNext Genzyme, Bone Care International Announce Shareholder Approval of … - Jun 30, 2005 Renagel is the only non-absorbed phosphate binder that controls ... The use of both Hectorol and Renagel is supported by a large and growing body of ... $4.95 - PR Newswire - ECNext Genzyme, Now In Front For AnorMED, Reports Earnings - Oct 13, 2006 Revenue for Renagel (sevelamer), a phosphate binder for patients with end-stage renal disease, grew to $134.7 million. Sales of another kidney drug, ... BioWorld Online - BioWorld Online Article: New dialysis centre for the poor - New Straits Times |... - May 21, 2007 Article: Renagel in New Dialysis Study Published in Kidney ... PR Newswire; January 8, ... Article: Renagel Study in New Dialysis Patients Published in ... ... Pay-Per-View - New Straits Times - HighBeam Research Genzyme第一å£åº¦ç›ˆåˆ©é™?至1.453亿美元 - Apr 23, 2008 ...第二大畅销è?¯Renagel销售é¢?较去年å?ŒæœŸå¤§å¢ž23%，至1.687亿美元。 ... 近期å?‘布的一份 报告，å?Žå°”街分æž?师æ¤å‰?预计Genzyme销售é¢?3.01亿美元，Renagel销售é¢?1.71亿 ... 新浪网 Press Release: Genzyme Reports Strong Fourth-Quarter Revenue … - Jan 11, 2005 Article: Renagel Study in New Dialysis Patients Published in Kidney . ... Data Show That Patients Treated with Renagel Achieve Mortality Benefit CAMBRIDGE . ... Pay-Per-View - PR Newswire - HighBeam Research Most patients on Renagel also receive calcium supplements, says... - Nov 28, 2005 Nabi Biopharmaceuticals, a USA-based drugmaker, has published the results of a study on the use of the drug Renagel (sevelamer), marketed by Genzyme, ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Article: Genzyme reports DCOR trial using Renagel in dialysis... - Aug 15, 2005 Renagel is a polymer that binds excess phosphorous in the blood. The study found that Renagel use resulted in the strongest clinical benefit in two groups ... Pay-Per-View - Transplant News - HighBeam Research Kidney Worries Hit Genzyme | Althea Chang News | Print Financial & … - Apr 21, 2005 Although Renagel prescriptions increased 19% during the first quarter, ... In the first quarter, Renagel brought in $99.4 million in revenue, compared with ... TheStreet.com - TheStreet.com (subscription) Genzyme to Participate in FDA Advisory Committee Meeting on the Use... - Oct 12, 2007 Renagel has been shown to effectively help patients achieve the target levels ... Renagel controls serum phosphorus in patients with chronic kidney disease ... $4.95 - PR Newswire - ECNext Zacks.com announces that Nadine Wong highlights: Genzyme. - Mar 22, 2006 The 2006 top-line growth will be derived from Renagel, which should benefit ... Renagel is approved for the control of serum phosphorus in patients with ... $4.95 - Business Wire - ECNext CORRECTION: GenzymeOs Renagel.(Correction Notice) - Aug 22, 2005 CORRECTION: In the August 8 issue of the Marketletter, we incorrectlty stated that the DCOR trial of Genzyme's Renagel was "the largest outcomes study ever ... $4.95 - Pharma Marketletter - ECNext Spectrum Pharmaceuticals Snags Altair's RenaZorb - Feb 7, 2005 The ESRD market, expected to be worth $500 million in 2005, according to Rodman & Renshaw, is currently dominated by Genzyme's Renagel. ... ICIS Event Brief of Q4 2004 Genzyme Corporation Earnings Conference Call -... - Feb 17, 2005 Full utilization of European manufacturing of Renagel in England & Ireland is now flowing ... Continue to see leverage in both the Therapeutics & Renagel ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genzyme Reports Second-Quarter GAAP EPS of $0.46, Non-GAAP EPS … - Jul 14, 2005 Within the Renal area, revenue for Renagel, a phosphate binder for ... Renagel revenue includes product sales, royalties and sales of bulk sevelamer. ... $4.95 - PR Newswire - ECNext … Results from DCOR Trial Favoring Use of Renagel. - PR Newswire |... - Jul 28, 2005 Long-term Use of Renagel Results in Lower Rates of Death ... The study found that Renagel use resulted in the strongest clinical benefit in two groups of ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q3 2006 Genzyme Corporation Earnings Conference Call -... - Oct 1, 2006 And so the use of Renagel is rarely compared against calcium because there's a ... And people choose Renagel for reasons of clinical benefit and that same ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Press Release: Genzyme Announces Results of Clinical Trials … - Jun 18, 2007 Phosphorus levels in the Renagel arm (4.6 mg/dL) were lower than those in the Renvela arm (5.3 mg/dL), and this trial did not achieve its primary endpoint ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme to buy Bone Care for $600M.(Pharmaceutical industry)(Brief … - May 16, 2005 ...is used to treat secondary hyperparathyroidism in patients on dialysis, where it can be used in tandem with Genzyme's Renagel (sevelamer HCl) and other ... $4.95 - Pharma Marketletter - ECNext Entrega de medicamentos para doença renal está atrasada no Paraná - Apr 18, 2008 O Renagel é fabricado pelo laboratório Genzyme ea distribuição é de exclusividade da Prohosp. O preço de tabela da unidade é de R$ 3,49. ... Jornale Curitiba Genzyme Reports Strong Fourth-Quarter Revenue Growth. - Jan 11, 2005 International sales of Renagel continued to be strong, particularly in Europe ... For the year, Renagel revenue was $364 million, up 29 percent from $282 ... $4.95 - PR Newswire - ECNext Genzyme "outperform" - Jan 9, 2008 So sei für "Renagel" mit einem Umsatz von 167 Mio. USD zu rechnen (Analystenprognose: 155 Mio. USD) und bei "Cerezyme" mit einem Umsatz von 301 Mio. ... AktienCheck Press Release: FDA Approves Genzyme's Renvela(TM) for Dialysis … - Oct 22, 2007 ..."Since its approval in 1998, Renagel has made an important difference for ... Today's approval of Renvela -- an improved form of Renagel -- is a key ... Pay-Per-View - PR Newswire - HighBeam Research Dialysis drug is cost effective, study. - Dec 2, 2005 The study of Renagel -- used to lower phosphorus levels in patients with ... The results suggested that Renagel did just that and could indeed be used in a ... Free with registration - UPI Health Business - AccessMyLibrary.com 洗腎者的ç¦?音～ 醫師：新磷çµ?å?ˆåŠ‘能é™?低患者5æˆ?æ»äº¡çŽ‡ - Dec 12, 2005 ...ç›®å‰?新開發的磷çµ?å?ˆåŠ‘Renagel(ç£·èƒ½è§£éŒ )，æˆ?分ä¸ä¸?å?«é‹?ã€?鈣或其他金屬æˆ?分，屬於å?«èƒº 基的è?šå?ˆç‰©ï¼Œç¾Žåœ‹è…Žè‡Ÿå¸ç§‘專家經é?Žè‡¨åºŠå¯¦é©—è‰æ˜Žï¼Œç™¼ç?¾ä½¿ç”¨ç£·èƒ½è§£éŒ 2年能é™?低æ»äº¡ ... NOWnews Kitamura Co Ltd acquires Kitamura Medical from Kitamura Holdings ( … - Sep 12, 2005 Gran Leukopenia M -- # CliniMACS Medical Device M -- # Renagel Hyperphosphatemia…Kirin Brewery Co.,LTD. Orphan Medical Inc ## KRN#### (cinacalcet) ... Pay-Per-View - deals - Alacra Store Lower death rate with long-term Renegal. - Aug 8, 2005 The study found that Renagel use resulted in the strongest clinical benefit in ... patients who used Renagel experienced a 9% reduced risk of death from all ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Nuova indicazione per Renagel - Jul 9, 2007 Nuove indicazioni in Europa per il farmaco Renagel (sevelamer HCl), fino ad ora approvato per il trattamento dell'iperfosforemia in pazienti adulti ... Pharma Marketing The Dialysis Clinical Outcomes Revisited (DCOR) Study - Jan 7, 2008 It would be appropriate at this point to point to the other study that was published just before the DCOR trial namely the RIND study, Renagel in New ... Medscape Event Brief of Q3 2006 Genzyme Corporation Earnings Conference Call -... - Oct 1, 2006 GENZ reported that after a strong 2Q06, Renagel worked beautifully in 3Q06. 1. Renagel has grown more ever since the introduction of competitive products ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Genzyme's Renvela well known, still looking to carve its niche - May 23, 2008 Like Renagel, Renvela is a calcium-free, metal-free, non-absorbed phosphate binder, according to Genzyme. The difference between the two drugs is that ... Renal Business Today BioTrends Releases Two Publications - TreatmentTrends(TM): … - May 6, 2008 Renagel maintains its position as market share leader in dialysis and Fosrenol's share is expected to significantly increase in this population. ... RedOrbit Rodrigo Renagel e Thadeu Braga - Nov 1, 2007 Ao saber para onde irÃamos no último sábado, 27, nossos amigos não largaram mais do nosso pé: "Sandy e Junior??? hehehe!! Agora fala sério, o que vocês vão ... O POVO Online Genzyme; Recent developments from Genzyme summarized - Dec 12, 2006 Most of our key products performed well, particularly Renagel, which showed ... Within the Renal division, revenue for Renagel (sevelamer hydrochloride), ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Genzyme Files for Approval of Sevelamer Carbonate for ... - Dec 21, 2006 Renagel controls serum phosphorus in patients with CKD on hemodialysis. ... Renagel provides the added benefit of significant LDL cholesterol reduction (32 ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme Corporation at Stanford Group Company Healthcare … - Jan 17, 2008 If you look at Renagel, for instance, in the renal business, ... You have seen Renagel growth accelerate in 2006 and '07 since we did the Bone Care ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genzyme: Geared for Growth - Jun 11, 2007 The company's next largest unit, Renal, is led by Renagel, a treatment to reduce elevated serum phosphorus in patients on kidney dialysis. ... BusinessWeek Biotech Stocks Turn It Around - Nov 14, 2005 Data presented Thursday morning at the annual meeting of the American Society of Nephrology indicated Renagel patients experienced a 9% reduced risk of ... Forbes Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue - Jan 9, 2006 Renagel revenue includes product sales, royalties and sales of bulk sevelamer. ... Both Renagel and Genzyme's Hectorol® (doxercalciferol) are positioned ... webwire.com Genzyme's 2004: Strong Sales, Growth Provided 'Stellar' Year - Jan 13, 2005 Renagel sales grew 22 percent in the fourth quarter of 2004 to $99 million. ... The results could support the use of Renagel in patients who are new to ... BioWorld Online - BioWorld Online Secretário anuncia processo contra fornecedores de medicamentos - Aug 10, 2007 De acordo com a secretaria de Saúde, a distribuidora do Renagel (Sevelamer) foi notificada para a entregar o medicamento em 24 horas, sob pena de ser ... O Dia Online Genzyme drugs get FDA approval - Oct 17, 2007 The drugs, called phosphate binders, include Genzyme's Renagel. ... Renagel is currently used in dialysis patients with late-stage kidney disease to absorb ... Boston Globe Отчет Genzyme за I квартал 2007 г. - Apr 27, 2007 Объем продаж компании выроÑ? на 21% и Ñ?оÑ?тавил 883,2 млн долл. СШÐ?. Ðтому Ñ?поÑ?обÑ?твовало увеличение объемов продаж препаратов Cerezyme, Fabrazyme и Renagel. ФармацевтичеÑ?кий веÑ?тник Zacks.com Announces That Nadine Wong Highlights: Genzyme. - Jun 16, 2005 Studies with Renagel have previously demonstrated that the progression of ... However, Renagel is widely believed to offer only equivalent phosphate binding ... $4.95 - Business Wire - ECNext Press Release: BioTrends Releases Two Publications - TreatmentTrends(... - May 6, 2008 Renagel maintains its position as market share leader in dialysis and Fosrenol's share is expected to significantly increase in this population. ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q1 2006 Genzyme Corporation Earnings Conference Call -... - Apr 19, 2006 Renagel, which was relatively stable in terms of revenues in the latter ... The expansion of Renagel beyond end stage renal disease towards CKD as sort of a ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude … - Jan 9, 2007 Within the Renal business, Genzyme markets Renagel® (sevelamer hydrochloride), ... Fourth-quarter revenue for Renagel grew 22 percent to $135 million, ... webwire.com Q1 2005 Genzyme Corporation Earnings Conference Call - Final. - Apr 21, 2005 And certainly, Renagel scrips during the quarter were up quarter-to-quarter. ... Renagel increased by 19% over Q1 of last year due to continued market ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Good Times for Phosphate Binders - Nov 30, 2007 Shire produces Fosrenol, Genzyme produces Renagel, and Fresenius produces PhosLo. ... “Today's approval of Renvela—an improved form of Renagel—is a key ... Renal Business Today Genzyme Delivers Excellent Fourth-Quarter and 2004 Performance ------... - Feb 17, 2005 Renagel revenue includes product sales, royalties and sales of bulk sevelamer. Renagel is a phosphate binder for patients with end-stage renal disease on ... $4.95 - PR Newswire - ECNext Genzyme Corp - Jun 19, 2006 ...include increased competition for Renagel and ... Renagel, a treatment to reduce elevated serum phosphorus in patients on kidney dialysis, is GENZ's sec- ... $35.00 - Stock Reports - Standard & Poor's FDA approves Genzyme's Renvela for dialysis patients. - Nov 1, 2007 Renvela is a next-generation version of the company's Renagel, ... The company says like Renagel, Renvela is a calcium-free, non-absorbed phosphate binder ... $4.95 - Transplant News - ECNext Stock Commentary - New York.(pharmaceutical and biotechnology … - Aug 8, 2005 In the biotechnology group, Genzyme rose 10.4% on positive results from a clinical trial of the firm's Renagel (sevelamer HCl) in dialysis patients (see ... $4.95 - Pharma Marketletter - ECNext Biotech Earnings: Second-Quarter Preview - Jul 8, 2008 Wall Street on average is looking for roughly $170 million to $173 million from Renagel/Renvela, $69 million from Myozyme, $309 million from Cerezyme and ... TheStreet.com - TheStreet.com (subscription) Genzyme Reports Financial Results for Fourth Quarter of 2006 and Full... - Feb 14, 2007 Sales of Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, are expected to reach $580-$590 ... webwire.com Biotech Earnings: Second-Quarter Preview - Jul 11, 2008 Wall Street on average is looking for roughly $170 million to $173 million from Renagel/Renvela, $69 million from Myozyme, $309 million from Cerezyme and ... TheStreet.com - TheStreet.com (subscription) Genzyme Corporation Analyst Meeting - Final. - May 6, 2005 It was an early phase of Renagel, very early phase of tolevamer ... But remember, in the case of GelTex, with the Renagel joint venture, it was, sort of, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Biotech Ready to Deliver - Oct 14, 2005 However, Nadeau believes another top seller, Renagel, used in about half of ... Nadeau is looking for Renagel sales of $102 million, compared with $93.3 ... TheStreet.com - TheStreet.com (subscription) Big Pharma Investors Place Their Bets - Oct 16, 2006 The firm has high expectations for new drugs Tolevamer and Mozibil and new indications for Renagel and Myozyme. "We believe none of these opportunities are ... Forbes Genzyme expects 2007 profit to rise on drug sales - Jan 9, 2007 Sales of the company's kidney disease drug Renagel rose 22 percent to $135 million. The company has submitted an application with US regulators for approval ... Reuters |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |